Business Transition Strategies

Hillevax, located in Boston, MA, is dedicated to advancing the development of a vaccine aimed at protecting against norovirus infection, which is recognized as the most common viral cause of acute gastroenteritis globally. The company focuses on addressing the significant public health challenge posed by norovirus, which is responsible for over 90% of epidemic non-bacterial gastroenteritis outbreaks worldwide. With an estimated 700 million cases and 200,000 deaths attributed to norovirus annually, the global economic burden is substantial, reaching approximately $60.3 billion. Hillevax aims to mitigate this impact through innovative vaccine solutions, contributing to improved health outcomes and reduced healthcare costs associated with norovirus infections. Generated from the website